Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

The S&P 500 finished the first half of the year with a win, but it wasn't without a struggle. Though the index had its ups, ...